Imbio RV/LV Software vs EchoGo Amyloidosis
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
These two tools are adjacent in their comparability, both leveraging AI for cardiac analysis but differing significantly in their imaging modality and specific clinical focus. Imbio RV/LV Software analyzes CTPA scans to assess ventricular dimensions for pulmonary conditions, while EchoGo Amyloidosis processes echocardiogram video clips for the early detection of cardiac amyloidosis. Therefore, the choice between them depends entirely on the specific imaging input available and the cardiac condition being investigated.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
Imbio RV/LV Software is designed to automatically measure right and left ventricular diameters from CTPA scans, providing an RV/LV ratio to aid in risk stratification for pulmonary conditions such as pulmonary embolism. EchoGo Amyloidosis is an AI-powered screening tool that analyzes echocardiogram video clips to aid in the early detection of cardiac amyloidosis.
Imbio RV/LV Software analyzes volumetric CTPA (Computed Tomography Pulmonary Angiography) scans. EchoGo Amyloidosis analyzes echocardiogram video clips, specifically a 2D echocardiogram of an apical four chamber (A4C).
Imbio RV/LV Software generates automated measurements of right and left ventricular diameters, calculates and reports the RV/LV ratio, provides annotated images, and creates summary PDF reports. EchoGo Amyloidosis provides a diagnostic output of 'suggestive' or 'not suggestive' of cardiac amyloidosis, based on its analysis of echocardiographic markers like ventricular volume, cardiac function, and myocardial movement.
Imbio RV/LV Software focuses on automated and consistent quantitative measurement, with research indicating automated analysis can change risk stratification in a significant percentage of patients. EchoGo Amyloidosis boasts high diagnostic accuracy with 85% sensitivity and 93% specificity for identifying suspected cardiac amyloidosis, demonstrating consistent performance across AL, wild-type ATTR, and variant ATTR subtypes.